Teva's ecopipam NDA gets FDA Priority Review for paediatric Tourette's

Teva Pharmaceuticals announced on 19 August 2026 that the US Food and Drug Administration has accepted its New Drug Application for ecopipam and granted Priority Review, setting a PDUFA action date in late Q1 2027. If approved, ecopipam would be the first therapy indicated specifically for paediatric Tourette syndrome to reach the market in more than ten years, and the first agent to work through a novel mechanism in over half a century.

Ecopipam is a selective dopamine D1 receptor antagonist, a distinct approach from the D2-blocking antipsychotics that have historically been repurposed for tic suppression. The candidate holds Orphan Drug designation, consistent with a condition estimated to affect around 100,000 children and adolescents in the United States. Teva's filing is supported by Phase 2b and Phase 3 data; the Phase 3 results were published earlier this year in JAMA Neurology.

Clinical data

The pivotal D1AMOND Phase 3 trial used a randomised withdrawal design, enrolling 216 paediatric and adult participants before randomising 104 of them, the majority paediatric, across 77 sites in North America and Europe. Responders assigned to placebo faced a 53% higher risk of relapse over 12 weeks compared with those who continued ecopipam (p=0.008). The accepted NDA and the indication Teva is seeking cover only the paediatric population.

Supporting data from the Phase 2b D1AMOND trial, a 12-week placebo-controlled study in 153 paediatric participants, showed statistically significant reduction in tic severity on the Yale Global Tic Severity Scale Total Tic Score versus placebo at week 12 (p=0.01). A subsequent open-label extension following participants for up to 12 months indicated durability of effect.

Across all three studies, ecopipam was reported to have no clinically meaningful impact on body weight, metabolic parameters, ECG readings, or markers of drug-induced movement disorder, which has been a limiting factor with older agents. The most commonly reported adverse events were headache, insomnia, fatigue, somnolence, tics, anxiety, nausea, and restlessness.

Eric Hughes, Executive Vice President of Global R&D and Chief Medical Officer at Teva, described the NDA acceptance as "an important milestone that advances Teva's Pivot to Growth strategy and brings us closer to addressing the unmet needs of children and their families affected by Tourette syndrome."

Market context and competitive landscape

The Tourette syndrome treatment landscape has remained largely static for decades. The three drugs with formal FDA approval in the indication are haloperidol (1969), pimozide (1984), and aripiprazole (2014). Real-world adherence is poor: published data cited by Teva suggest that only 20 to 30 percent of treated patients remain on D2-blocking therapy after one year, largely owing to side-effect burden including sedation, weight gain, and movement disorders. This adherence gap is central to the commercial rationale for a D1-selective mechanism.

Ecopipam was originally developed by Psyadon Pharmaceuticals before Teva acquired the programme. The D1 receptor pathway has attracted limited pharmaceutical investment relative to D2, in part because earlier D1 antagonists showed unfavourable profiles in other indications. Teva's clinical package appears to have navigated the tolerability concerns that stalled predecessors, though prescribers will look carefully at the full label once available.

Priority Review status shortens the standard FDA review clock from twelve months to six, which aligns with the Q1 2027 PDUFA date. Orphan Drug designation will, if approval is granted, provide Teva with seven years of US market exclusivity. The company has not publicly disclosed a commercial pricing strategy or launch infrastructure plans ahead of the regulatory decision.